12:00 AM
Jan 23, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Nypta tideglusib: Completed Phase IIb enrollment

Noscira completed enrollment of 308 patients with mild to moderate AD in the double-blind, placebo-controlled, European Phase IIb ARGO trial evaluating once-daily 500 and 1,000 mg oral Nypta tideglusib and 1,000 mg Nypta given every other...

Read the full 156 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >